1998
DOI: 10.1016/s0198-8859(97)00255-3
|View full text |Cite
|
Sign up to set email alerts
|

The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
130
0

Year Published

1999
1999
2008
2008

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 196 publications
(132 citation statements)
references
References 58 publications
2
130
0
Order By: Relevance
“…We conclude that this recognition was MHC class I-restricted, as a HER-2 expressing, but HLA-A2.1-negative, tumor was not recognized. In line with these findings, Kawashima et al (34) were able to identify double-substitution analogues from CEA with strong tumor-specific immunogenicity in vitro, and others have found that double or single substitution of CTL epitopes is able to induce tumor-specific T cells (8 -11, 17, 29, 30).…”
Section: Discussionmentioning
confidence: 75%
“…We conclude that this recognition was MHC class I-restricted, as a HER-2 expressing, but HLA-A2.1-negative, tumor was not recognized. In line with these findings, Kawashima et al (34) were able to identify double-substitution analogues from CEA with strong tumor-specific immunogenicity in vitro, and others have found that double or single substitution of CTL epitopes is able to induce tumor-specific T cells (8 -11, 17, 29, 30).…”
Section: Discussionmentioning
confidence: 75%
“…The identification of several new HLA-A2-restricted CTL epitopes from HER-2/neu that can activate CTLs from healthy donors and patients with advanced ovarian carcinoma has also been reported. 14,15 These results indicate that HER-2/neu-derived peptides could be broad targets for immunotherapy against these types of cancers. It is important to evaluate candidates for tumor vaccination with HER-2/neu-derived peptides in patients with gastric cancer.…”
mentioning
confidence: 96%
“…[110][111][112][113] However, it was observed that numerous CTL that were raised against high-affinity binding peptides did not recognize tumor cells expressing the relevant TAA and restriction element. [114][115][116][117][118] A major reason for this was the lack of intracellular generation of predicted peptides by the processing machinery.…”
Section: Identification Of T-cell Epitopes For Cancer Immunotherapy Jmentioning
confidence: 99%